ApprovedFDA approval

Revtorpyk (gedatolisib)

Celcuity (CELC)

Marketer take

Labeled for HR+/HER2- breast cancer without a PIK3CA mutation, a different slice of post-endocrine disease than PI3K-pathway drugs aimed at mutated tumors, so biomarker results will steer the oncologist conversation.

Sponsor company
Celcuity (CELC)
Indication
In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting
Therapeutic area
Oncology
Event
FDA approval
Date
Jul 14, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move